Trial Profile
An Open-label, Single Dose, Parallel Design, Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Oral Dosage Form of LCB01-0371 in Healthy Volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Delpazolid (Primary)
- Indications Bacterial infections; Gram-positive infections
- Focus Pharmacokinetics
- Sponsors LegoChem Biosciences
- 07 Apr 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 25 Aug 2015 New trial record